The UBC-linked antibody drug developer has added $73m to its initial public offering, and its shares are still trading at more than double the IPO price.

Stanford-StartX Fund is set to exit payment processing technology provider Poynt in an acquisition sized at up to $365m.

The Eli Lilly-backed antibody drug developer has added $73m to its initial public offering, and its shares are still trading at more than double the IPO price.

University of Florida has backed a second round for Atsena, a vision loss therapy developer exploiting inventions the institution had originally licensed to Sanofi.

The GV-backed consumer goods marketplace hit a $2.8bn valuation in a Tiger Global-led series E round, which brings its total funding to $490m.

Rakuten, Progressive and GV-backed online lending platform developer floated at the bottom of its range before a first-day pop.

Junshi Biosciences has invested in the University of Birmingham-founded cancer immunotherapy developer, building on a research collaboration deal.

Pfizer Ventures-backed cancer drug developer BioAtla's shares popped on its first day of trading yesterday following a $189m initial public offering.

Blue Venture Fund returned as part of the latest funding to be raised by the mobile substance abuse treatment service.

Amazon Climate Pledge Fund and Shell Ventures both participated in a $21.4m round that will support development of ZeroAvia's hydrogen aircraft powertrain.